Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-04-03 DOI:10.1007/s00277-025-06340-y

Paul Mobascher, Monika Engelhardt, Ralph Wäsch

引用次数: 0

Abstract

We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti^®) after achieving a partial but not durable remission with Idecabtagene Vicleucel (ide-cel, Abecma^®). Both CAR T-cells target the B-cell maturation antigen (BCMA) and their sequential use is as yet rare, thus data on safety and efficacy of their sequential employment are precious and relevant for the myeloma commmunity.

查看原文本刊更多论文

我们在此报告了一名复发-难治性多发性骨髓瘤（RRMM）患者的情况，该患者在使用Idecabtagene Vicleucel（ide-cel，Abecma®）获得部分缓解但不持久后，接受了嵌合抗原受体（CAR）T细胞（Ciltacabtagene Autoleucel，cilta-cel，Carvykti®）治疗。这两种CAR T细胞都以B细胞成熟抗原（BCMA）为靶点，而且它们的连续使用目前还很少见，因此有关它们连续使用的安全性和有效性的数据非常珍贵，与骨髓瘤界息息相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.